Unfortunately, to date, the HDAC inhibitor SAHA has demonstrated little efficacy in endometrial cancer Phase II trials, [25] likely due to factors including poor stability in circulation and lack of accumulation at effective concentrations at the tumor sites due to poor tumor penetration and drug efflux [26]. Here, HDAC9 is linked to neoplasm.